Why Did Unity Biotechnology Stock Fall? The reason for Unity's stock value falling is directly tied to the results of its second-phase clinical results for UBX0101. The drug is meant to treat moderate to severe osteoarthritis (OA) in the knee.
Will UNITY Biotechnology stock go up?
Stock Price Forecast The 7 analysts offering 12-month price forecasts for UNITY Biotechnology Inc have a median target of 6.00, with a high estimate of 12.00 and a low estimate of 4.00. The median estimate represents a +415.02% increase from the last price of 1.17.
Is UNITY Biotechnology a good buy?
Valuation metrics show that UNITY Biotechnology, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of UBX, demonstrate its potential to underperform the market.
Who invested in UNITY Biotechnology?
Stockholder Stake Shares owned
---------------------------- ----- ------------
The Vanguard Group, Inc. 2.41% 1,390,736
BlackRock Fund Advisors 1.50% 867,108
Renaissance Technologies LLC 1.11% 640,700
Baillie Gifford & Co. 1.02% 589,111
Is Unity Software A Buy Sell or Hold?
Unity Software has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.
What happened to UNITY Biotechnology?
Type Public
------- ----------------------
Website unitybiotechnology.com
Who is investing in UNITY Biotechnology?
Stockholder Stake Total value ($)
------------------------------------ ----- ---------------
Fidelity Management & Research Co 6.20% 5,221,423
The Vanguard Group, Inc. 2.41% 2,030,475
BlackRock Fund Advisors 1.50% 1,265,978
Renaissance Technologies LLC 1.11% 935,422
What is unity biotech working on?
At UNITY we are developing therapeutics to slow, halt, or reverse diseases of aging. Age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burden for individuals, their families, and broader communities.